(Q37977315)

26 August 2017

title

Antidotes for toxicological emergencies: a practical review (English)

1 reference

26 August 2017

Jeanna M Marraffa

1

1 reference

26 August 2017

Victor Cohen

series ordinal

2

1 reference

26 August 2017

Mary Ann Howland

series ordinal

3

1 reference

26 August 2017

publication date

1 February 2012

1 reference

American Journal of Health-System Pharmacy

26 August 2017

published in

1 reference

26 August 2017

volume

69

1 reference

26 August 2017

issue

3

1 reference

26 August 2017

page(s)

199-212

1 reference

2009 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 27th Annual Report

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Poisoning deaths not reported to the regional poison control center

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Accidental and suicidal adolescent poisoning deaths in the United States, 1979-1994.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Fomepizole for the treatment of methanol poisoning

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Fomepizole for the treatment of ethylene glycol poisoning. Methylpyrazole for Toxic Alcohols Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

American Academy of Clinical Toxicology practice guidelines on the treatment of methanol poisoning

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

2008 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 26th Annual Report

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Outcomes of visual disturbances after methanol poisoning

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Fatal renal failure caused by diethylene glycol in paracetamol elixir: the Bangladesh epidemic

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Diethylene glycol poisoning in Nigerian children

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Fulminant ascending paralysis as a delayed sequela of diethylene glycol (Sterno) ingestion

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Diethylene glycol: widely used solvent presents serious poisoning potential

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Encephalopathy and peripheral neuropathy following diethylene glycol ingestion.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Delayed neurologic sequelae resulting from epidemic diethylene glycol poisoning

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Fatal encephalopathy and renal failure caused by diethylene glycol poisoning

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Antidotes for methanol and ethylene glycol poisoning

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Plasma and tissue determination of 4-methylpyrazole for pharmacokinetic analysis in acute adult and pediatric methanol/ethylene glycol poisoning

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Methanol toxicity: treatment with folic acid and 5-formyl tetrahydrofolic acid

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Role of pyridoxine in oxalate metabolism

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Comparative studies on the effect of vitamin A, B1 and B6 deficiency on oxalate metabolism in male rats

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Management of beta-adrenergic blocker and calcium channel antagonist toxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Pharmacology, pathophysiology and management of calcium channel blocker and beta-blocker toxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Assessment of hyperglycemia after calcium channel blocker overdoses involving diltiazem or verapamil

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Hyperinsulinemia/euglycemia therapy for calcium channel blocker poisoning

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Insulin-glucose as adjunctive therapy for severe calcium channel antagonist poisoning

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

The actions of insulin on cardiac contractility

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

The role of insulin and glucose (hyperinsulinaemia/euglycaemia) therapy in acute calcium channel antagonist and beta-blocker poisoning

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Bench-to-bedside review: hyperinsulinaemia/euglycaemia therapy in the management of overdose of calcium-channel blockers

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Beneficial myocardial metabolic effects of insulin during verapamil toxicity in the anesthetized canine

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

The effects of extracellular ions on beta-blocker cardiotoxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

High-dose insulin therapy in beta-blocker and calcium channel-blocker poisoning

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Cyanide poisoning in victims of fire: analysis of 364 cases and review of the literature.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Focus on smoke inhalation--the most common cause of acute cyanide poisoning.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Hydroxocobalamin for poisoning caused by ingestion of potassium cyanide: a case study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Value of lactic acidosis in the assessment of the severity of acute cyanide poisoning

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Nitrite and thiosulfate therapy in cyanide poisoning

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Ferrihaemoglobin formation by amyl nitrite and sodium nitrite in different species in vivo and in vitro.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Hydroxocobalamin for severe acute cyanide poisoning by ingestion or inhalation

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Prehospital administration of hydroxocobalamin for smoke inhalation-associated cyanide poisoning: 8 years of experience in the Paris Fire Brigade

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Efficacy of hydroxocobalamin for the treatment of acute cyanide poisoning in adult beagle dogs

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Safety of hydroxocobalamin in healthy volunteers in a randomized, placebo-controlled study.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Hemodialysis complications of hydroxocobalamin: a case report

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Discoloration of skin and urine after treatment with hydroxocobalamin for cyanide poisoning

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Effect of the cyanide antidote hydroxocobalamin on commonly ordered serum chemistry studies

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Laboratory interferences with the newer cyanide antidote: hydroxocobalamin

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Hydroxocobalamin and cyanocobalamin interference on co-oximetry based hemoglobin measurements

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Digoxin Immune Fab therapy in the management of digitalis intoxication: safety and efficacy results of an observational surveillance study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Results of multicenter studies of digoxin-specific antibody fragments in managing digitalis intoxication in the pediatric population

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments. Final report of a multicenter study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Assessment of digoxin antibody use in patients with elevated serum digoxin following chronic or acute exposure

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Digoxin-specific Fab fragments as single first-line therapy in digitalis poisoning

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Contamination of botanical dietary supplements by Digitalis lanata

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Immunotoxicotherapy: successes, disappointments and hopes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Digoxin specific antibody (Fab) fragments in 34 cases of severe digitalis intoxication

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Advances in the management of digoxin toxicity in the older patient

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

The distribution and concentration of tritiated digoxin in human tissues

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Plasma digoxin: assay anomalies in Fab-treated patients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Flumazenil: a pharmacologic antidote with limited medical toxicology utility, or ... an antidote in search of an overdose

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Fatal seizures after flumazenil administration in a patient with mixed overdose

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Seizures after flumazenil administration in a case of combined benzodiazepine and tricyclic antidepressant overdose

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Flumazenil--treatment or toxin

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Lipid rescue resuscitation from local anaesthetic cardiac toxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Lipid infusion resuscitation for local anesthetic toxicity: proof of clinical efficacy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Lipid emulsion infusion rescues dogs from bupivacaine-induced cardiac toxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Limits to lipid in the literature and lab: what we know, what we don't know

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Lipid infusion therapy: translation to clinical practice

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Resuscitation with lipid versus epinephrine in a rat model of bupivacaine overdose

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Epinephrine impairs lipid resuscitation from bupivacaine overdose: a threshold effect

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Early use of lipid emulsion to treat incipient mepivacaine intoxication.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Reversal of central nervous system and cardiac toxicity after local anesthetic intoxication by lipid emulsion injection

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Immediate lipid emulsion therapy in the successful treatment of bupivacaine systemic toxicity.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Successful use of a 20% lipid emulsion to resuscitate a patient after a presumed bupivacaine-related cardiac arrest

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Lipid, not propofol, treats bupivacaine overdose

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Hemodynamic effects of intravenous fat emulsion in an animal model of severe verapamil toxicity resuscitated with atropine, calcium, and saline

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Correlation of plasma and peritoneal diasylate clomipramine concentration with hemodynamic recovery after intralipid infusion in rabbits

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Determining the optimal dose of intravenous fat emulsion for the treatment of severe verapamil toxicity in a rodent model

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Use of lipid emulsion in the resuscitation of a patient with prolonged cardiovascular collapse after overdose of bupropion and lamotrigine

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Hemodynamic effects of intralipid after verapamil intoxication may be due to a direct effect of fatty acids on myocardial calcium channels

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Safety of high volume lipid emulsion infusion: a first approximation of LD50 in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Improved outcome of paracetamol-induced fulminant hepatic failure by late administration of acetylcysteine

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: a prospective controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Intravenous N-acetylcystine: the treatment of choice for paracetamol poisoning

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985)

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Risk of recurrence of birth defects

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

N-acetylcysteine prevents carbon tetrachloride-induced liver cirrhosis: role of liver transforming growth factor-beta and oxidative stress.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

N-acetyl cysteine is an early but also a late preventive agent against carbon tetrachloride-induced liver necrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Acute chloroform ingestion successfully treated with intravenously administered N-acetylcysteine

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Pennyroyal toxicity: measurement of toxic metabolite levels in two cases and review of the literature

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Comparison of the 20-hour intravenous and 72-hour oral acetylcysteine protocols for the treatment of acute acetaminophen poisoning.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Intravenous N-acetylcysteine: still the treatment of choice for paracetamol poisoning.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Acetylcysteine for acetaminophen poisoning

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Placental transfer of N-acetylcysteine following human maternal acetaminophen toxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Transplacental transport of N-acetylcysteine in an ovine model.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Patient-tailored acetylcysteine administration.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Treatment of drug overdosage with naloxone, a specific narcotic antagonist

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Use of naloxone in opiate poisoning

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Nalmefene: safety and kinetics after single and multiple oral doses of a new opioid antagonist

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Actions of morphine on noradrenaline efflux in the rat locus coeruleus are mediated via both opioid and alpha 2 adrenoceptor mechanisms

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Clonidine toxicity revisited

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Central nervous system manifestations of an ibuprofen overdose reversed by naloxone

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Use of naloxone in valproic acid overdose: case report and review

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Chronic valproic acid intoxication: reversal by naloxone

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Naloxone reversal of hypotension due to captopril overdose

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Incidence, Reversal, and Prevention of Opioid-induced Respiratory Depression

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Naloxone reversal of opioid-induced respiratory depression with special emphasis on the partial agonist/antagonist buprenorphine

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Naloxone reversal of buprenorphine-induced respiratory depression

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Mechanism-based pharmacokinetic-pharmacodynamic modelling of the reversal of buprenorphine-induced respiratory depression by naloxone : a study in healthy volunteers

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

A dosing nomogram for continuous infusion intravenous naloxone.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Comparison of octreotide and standard therapy versus standard therapy alone for the treatment of sulfonylurea-induced hypoglycemia

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Case files of the Medical Toxicology Fellowship Training Program at the Children's Hospital of Philadelphia: a pediatric exploratory sulfonylurea ingestion

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Octreotide: an antidote for sulfonylurea-induced hypoglycemia

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Effectiveness of octreotide in a case of refractory sulfonylurea-induced hypoglycemia

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Octreotide in children with hypoglycaemia due to sulfonylurea ingestion

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Extended-release glipizide overdose presenting with delayed hypoglycemia and treated with subcutaneous octreotide.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

Safety of subcutaneous octreotide in patients with sulfonylurea-induced hypoglycemia and congestive heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110014

31 March 2020

Identifiers

DOI

10.2146/AJHP110014

1 reference

26 August 2017

1 reference